Lilly says it plans to launch weight-loss pill orforglipron in India

Eli Lilly plans to launch its experimental obesity pill orforglipron in India, a senior executive said on September 25, 2025, offering an alternative to injectable GLP-1 drugs that many patients in the world's most populous nation resist ^[1].

Winselow Tucker, president of Lilly India, said at an industry conference panel in Mumbai that there is "promise for products like that in India, if it gets approved" ^[1]. He did not give a launch timeline ^[1].

Orforglipron is part of a new class of GLP-1 drugs that suppress appetite ^[1]. It follows the same pathway targeted by Eli Lilly's tirzepatide, which is sold as Mounjaro for diabetes and Zepbound for weight loss ^[1]. The pill has not been launched anywhere in the world, and Lilly plans to file for approval with regulators in the United States, Britain, the European Union, Japan and China ^[1]. It was not immediately clear whether the company has started an approval procedure for orforglipron in India ^[1].

The latest trial data showed orforglipron lowered blood sugar and weight more effectively than Novo Nordisk's older GLP-1 drug Rybelsus in adults with type 2 diabetes ^[1].

Novo Nordisk India head Vikrant Shrotriya said people in India would take their tablets rather than inject ^[1]. Tucker added that stigma and logistical hurdles also weigh on injectables ^[1]. Still, both companies remain upbeat on the market. Novo's Wegovy and Lilly's Mounjaro, launched in India earlier this year, have seen demand surge, with sales doubling within months ^[1]. "We are seeing growing acceptance of obesity injectables in India," Shrotriya said ^[1].

Orforglipron is a different molecule from the GLP-1 medicines now on the US market, and it is still experimental ^[1].

Why it matters for patients

Orforglipron has not been launched anywhere, so it is not available to patients in the United States or any other country right now ^[1]. Lilly has said it plans to file for approval with US regulators, but no filing date, review timeline or expected decision has been disclosed ^[1].

The India announcement does not change US availability or timing. It shows that Lilly sees a market for an oral GLP-1 and that the company is thinking about the distribution costs and patient resistance that come with injections ^[1]. In India, both Novo Nordisk and Lilly say injectable obesity drugs are already selling, with sales doubling within months of their launches earlier this year ^[1].

A pill form could matter for people who dislike injections or who cannot manage cold-chain storage, though the article does not report how orforglipron compares with tirzepatide or semaglutide on weight loss in people with obesity, rather than type 2 diabetes ^[1]. The trial result described compares orforglipron with Rybelsus in adults with type 2 diabetes only ^[1].

How much orforglipron would cost in India or the United States, and whether it would be priced below injectables, has not been reported ^[1].

What happens next

Lilly plans to file orforglipron for approval with regulators in the United States, Britain, the European Union, Japan and China ^[1]. No dates for those filings have been disclosed ^[1].

Lilly has not said when it would launch orforglipron in India, and it is not yet clear whether it has begun the approval process there ^[1].

In India, the near-term signal is the injectable market: Novo's Wegovy and Lilly's Mounjaro arrived earlier this year and sales doubled within months, according to the two companies ^[1].